4-辛基苯乙酮 | 37062-63-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-辛基苯乙酮
• 中文别名: 4－辛基苯乙酮
• 英文名称: 1-(4-octyloxy-phenyl)-ethanone
• 英文别名: 4-octyloxyacetophenone；4'-Octyloxyacetophenone；1-(4-octoxyphenyl)ethanone
• CAS: 37062-63-8
• 化学式: C₁₆H₂₄O₂
• mdl: MFCD00143208
• 分子量: 248.365
• InChiKey: VPKXMEDAPFGBQW-UHFFFAOYSA-N

物化性质

• 熔点：
  30-32 °C
• 沸点：
  197.74°C (rough estimate)
• 密度：
  0.8260 (rough estimate)
• 稳定性/保质期：
  常规情况下不会分解，也没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.562
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2914509090
• 储存条件：
  请将密封、阴凉、干燥、通风的环境用于保存。

SDS

Name:	4 -Octyloxyacetophenone 99.5+% Material Safety Data Sheet
Synonym:	1-[(4-Octyloxy)phenyl)]1-ethanon
CAS:	37062-63-8

Section 1 - Chemical Product MSDS Name:4 -Octyloxyacetophenone 99.5+% Material Safety Data Sheet
Synonym:1-[(4-Octyloxy)phenyl)]1-ethanon

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
37062-63-8	4'-Octyloxyacetophenone	99.5%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Sweep up, then place into a suitable container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 37062-63-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: beige
Odor: None reported.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C6H24O2
Molecular Weight: 128.26

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 37062-63-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4'-Octyloxyacetophenone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 37062-63-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 37062-63-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 37062-63-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-辛基苯乙酮 在 硝酸 、 sodium nitrite 作用下， 以 溶剂黄146 为溶剂， 反应 12.0h， 以74%的产率得到3,4-di(p-octyloxybenzoyl)furoxan
  参考文献：
  名称：

  Mataka, Shuntaro; Misumi, Osamu; Lin, Wei Hua, Journal of Heterocyclic Chemistry, 1992, vol. 29, # 1, p. 87 - 92

  摘要：

  DOI：
• 作为产物：
  描述：

  苯酚 在 二硫化碳 、 氢氧化钾 、 三氯化铝 作用下， 生成 4-辛基苯乙酮
  参考文献：
  名称：

  756. α -Methylbenzylamines。第二部分 3-环己氧基-4-羟基-α-甲基苄胺，其脱氧衍生物及相关醚

  摘要：

  DOI：

  10.1039/jr9510003430

文献信息

• Mesogenic heterocycles formed by bis-pyrazoles and bis-1,3,4-oxadiazoles
  作者：Kuan-Ting Lin、Gene-Hsiang Lee、Chung K. Lai

  DOI：10.1016/j.tet.2015.04.055

  日期：2015.6

  Three new series of compounds 1a–c containing multiple heterocyclic 2,5-pyrazoles, 1,3,4-oxadiazole and thiophene exhibiting mesophases were reported. Crystallographic data showed that the crystal 1a (n=8) is a linear-shaped molecule with a molecular length of ca. 40.57 Å. However, three heterocyclic rings were not coplanar. All compounds 1a formed smectic A/C phases, and all compounds 1c exhibited columnar

  报道了三个新的系列化合物1a – c，其中包含多个显示中间相的杂环2,5,5-吡唑，1,3,4-恶二唑和噻吩。晶体学数据表明，晶体1a（n = 8）是线型分子，分子长为。40.57Å。但是，三个杂环不是共面的。所有化合物1a均形成近晶A / C相，并且所有化合物1c均显示出柱状相，这通过粉末X射线衍射仪（XRD）证实。对于导数1c，在9.0埃厚的切片中获得了一个N电池，R ar值等于3.91和18.29Å（n = 8），表明在Col h相的列内两个分子是相关的。通过热重分析（TGA），所有衍生物在T = 383–426°C以下的温度下均表现出良好的稳定性。所有化合物的PL光谱图1b - Ç（Ñ = 8）显示出一个强峰在λ最大= 428-496纳米，且这些光致发光发射（PL）源自1,3,4-恶二唑基部分。
• [EN] (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS<br/>[FR] DÉRIVÉS DE (THIO)MORPHOLINE MODULATEURS DE S1P
  申请人：ABBOTT HEALTHCARE PRODUCTS BV

  公开号：WO2011023795A1

  公开（公告）日：2011-03-03

  The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

  本发明涉及公式（I）的（硫）吗啉衍生物，其中R1从氰基，（2-4C）炔基，（1-4C）烷基，（3-6C）环烷基，（4-6C）环烯基，（6-8C）双环烷基，（8-10C）双环基团中选择，每个基团可选择地取代为（1-4C）烷基，苯基，联苯基，萘基，每个基团可选择地取代为一个或多个取代基，独立选择自卤素，（1-4C）烷基可选择地取代为一个或多个氟原子，（2-4C）炔基，（1-4C）氧烷基可选择地取代为一个或多个氟原子，氨基，二（1-4C）烷基氨基，-SO2-（1-4C）烷基，-CO-（1-4C）烷基，-CO-O-（1-4C）烷基，-NH-CO-（1-4C）烷基和（3-6C）环烷基，苯基取代为苯氧基，苄基，苄氧基，苯乙基或单环杂环烃，每个基团可选择地取代为（1-4C）烷基，单环杂环烃可选择地取代为卤素，（1-4C）烷基或取代为苯基的苯基，可选择地取代为（1-4C）烷基，和双环杂环烃可选择地取代为（1-4C）烷基；A从-CO-O-，-O-CO-，-NH-CO-，-CO-NH，-C=C-，-CCH3-O-和连接基-Y-（CH2）n-X-中选择，其中Y连接到R1并从键，-O-，-S-，-SO-，-SO2-，-CH2-O-，-CO-，-O-CO-，-CO-O-，-CO-NH-，-NH-CO-，-C=C-和-C≡C-中选择；n是1到10的整数；X连接到苯基/吡啶基团并从键，-O-，-S-，-SO-，-SO2-，-NH，-CO-，-C=C-和-C≡C-中选择；环结构B可选择地含有一个氮原子；R2是H，（1-4C）烷基可选择地取代为一个或多个氟原子，（1-4C）氧烷基可选择地取代为一个或多个氟原子，或卤素；R3是（1-4C）烷基-R5，其中烷基基团可取代为（CH2）2形成环丙基基团或一个或两个卤素原子，或R3是（3-6C）环烷基-R5或-CO-CH2-R5，其中R5是-OH，-PO3H2，-OPO3H2，-COOH，-COO（1-4C）烷基或四唑-5-基；R4是H或（1-4C）烷基；R6是一个或多个取代基，独立选择自H，（1-4C）烷基或氧代基；W是-O-，-S-，-SO-或-SO2-；或其药学上可接受的盐，溶剂或水合物；但是，公式（I）的衍生物不是2-（4-乙基苯基）-4-吗啉乙醇或4-[4-（2-羟乙基）-2-吗啉基]苯乙腈或其药学上可接受的盐，溶剂或水合物。本发明的化合物具有对S1P受体的亲和力，可用于治疗、缓解或预防S1P受体介导的疾病和症状。
• Fluorescent columnar bis(boron difluoride) complexes derived from tetraketonates
  作者：Ya-Wen Chen、Yen-Chun Lin、Hsiu-Ming Kuo、Chung K. Lai

  DOI：10.1039/c7tc01425b

  日期：——

  of bis-(boron difluoride) complexes 1a–c derived from substituted tetraketonates 2a–c are reported, and their mesomorphic and optical properties have been investigated. Two single crystals of mesogenic ligand 2a (n = 6) and nonmesogenic diboron complex 1a (n = 14) were obtained, and their single crystal and molecular structures were resolved. Results show that all 2a ligands (n = 6, 8, 10, 12, 14) formed

  据报道，由取代的四酮酸酯2a-c衍生出三个新的双-（二氟化硼）配合物1a-c系列，并研究了它们的介晶和光学性质。获得了两个介晶配体2a（n = 6）和非介晶二硼配合物1a（n = 14）的单晶，并解析了它们的单晶和分子结构。结果表明，所有2a配体（n = 6、8、10、12、14）均形成向列和/或近晶C相。但是，所有2b–c化合物都不是介晶的。相反，bis（BF 2）络合物1a–b是非介晶的，1c（n = 8、10、12）表现出对映体柱状中间相。对于化合物1c，在9.0埃厚的柱层中获得了N cell = 2.70–2.86 ，这表明在Col h相中，单个盘状分子堆叠在柱中。在室温下，Bis（BF 2）络合物1a–c（n = 8）在溶液中具有明显的黄红色发射。发光发射显示对结构部分有很强的依赖性结合，与λ最大= 538（1A）<641（图1b）<708纳米（1C）。据我们所知，这是柱状bis（BF
• Mesomorphic 1,2,4-triazine-4-oxides in the synthesis of new heterocyclic liquid crystals
  作者：Valery N. Kozhevnikov、Stephen J. Cowling、Peter B. Karadakov、Duncan W. Bruce

  DOI：10.1039/b718432h

  日期：——

  New liquid-crystalline materials are described, which are obtained using a versatile synthetic methodology that employs the intermediacy of 1,2,4-triazines. Triazines, triazine-N-oxides, pyridine and laterally cyanated pyridines are among the compounds reported and the mesomorphism of the different structures shows how function affects mesomorphism. In particular, systems based on laterally cyanated pyridines turn out to be materials with low melting points and wide phase ranges. Lateral dipole moments, calculated at the Hartree–Fock level for the triazine-N-oxides and the cyanopyridines, showed a significant dependence on conformation and confirmed that the dipole moment was great for the latter materials. Appreciable spontaneous polarisation was measured for chiral derivatives of the triazine-N-oxides.

  新描述的液晶材料，是通过一种多功能的合成方法获得的，该方法利用了1,2,4-三嗪的中间体。报道的化合物包括三嗪、三嗪-N-氧化物、吡啶及其侧链氰化的吡啶，不同结构的液晶性展示了功能如何影响液晶性。特别是基于侧链氰化吡啶的系统，显示出低熔点和宽相范围的特性。计算得出的侧链偶极矩，对三嗪-N-氧化物和氰化吡啶在Hartree-Fock水平上显示出对构象的显著依赖性，并确认了后者材料的偶极矩较大。对三嗪-N-氧化物的手性衍生物测量到了显著的自发极化。
• 2-FLUORO-1,3-BENZODITHIOL 1,1,3,3-TETRAOXIDE DERIVATIVE, PRODUCTION METHOD THEREOF, AND PRODUCTION METHOD OF MONOFLUOROMETHYL GROUP-CONTAINING COMPOUND USING THE SAME
  申请人：Shibata Norio

  公开号：US20110319637A1

  公开（公告）日：2011-12-29

  A 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative as a monofluoromethyl group introduction agent that is effective as an intermediate in pharmaceutical and agrochemical synthesis, a production method thereof, and a production method of a monofluoromethyl group-containing compound using this 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative are provided. The 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative represented by the following general formula (1) (wherein R 1 , R 2 , R 3 , and R 4 each independently represent a hydrogen atom, a straight-chain or branched alkyl group having 1 to 4 carbon atoms, a straight-chain or branched alkyloxy group having 1 to 4 carbon atoms, a halogen atom, a nitro group, or a cyano group), the production method thereof, and various monofluoromethyl group-containing compounds are manufactured using this 2-fluoro-1,3-benzodithiol 1,1,3,3-tetraoxide derivative as a monofluoromethylating agent.

  一种2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物作为单氟甲基基团引入剂，可作为制药和农药合成中间体，提供其生产方法，以及使用该2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物制备含单氟甲基基团的化合物的生产方法。所述2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物由下述通用式（1）表示（其中R1、R2、R3和R4各自独立地表示氢原子、具有1至4个碳原子的直链或支链烷基基团、具有1至4个碳原子的直链或支链烷氧基基团、卤素原子、硝基团或氰基团），提供其生产方法，并使用该2-氟-1,3-苯二硫醚-1,1,3,3-四氧化物衍生物作为单氟甲基化剂制造各种含单氟甲基基团的化合物。